May 18 is the 22nd anniversary of HIV Vaccine Awareness Day (HVAD), a day when partners around the world join to celebrate the people, partnerships and science pushing ever closer to a safe, efficacious and accessible vaccine against HIV.
With three HIV vaccine efficacy trial programs currently underway—a first for the field—and many new discoveries from lab and clinical research, AVAC is excited by the momentum and progress as of 2019.
On the other hand, we’re alarmed by a global rise in what is sometimes called “vaccine hesitancy”, marked by measles outbreaks and a comeback of a disease almost eradicated through vaccination. Misinformation about vaccines could undo decades of progress in public health.
This HIV Vaccine Awareness Day, it’s time for a new global commitment to vaccine research, development and delivery.
HVAD Webinars
HIV Vaccine Science and Advocacy Priorities this HVAD
On May 16, Mary Marovich, the Director of the Vaccine Research Program at the Division of AIDS at the National Institute of Allergy and Infectious Diseases, and long-time HIV vaccine research advocate and community leader, Mark Hubbard, discussed the current landscape of vaccine research.
Recording: YouTube / Audio / Introductory Slides / Mary Marovich's Slides
Growing Epidemic of Vaccine Hesitancy and the Implications for Global Health
On Thursday May 23, Heidi Larson, Director of the Vaccine Confidence Project discussed the implications of vaccine hesitancy and other issues along with Laura Lopez Gonzalez, deputy editor of South Africa’s Bhekisisa Health Journalism Centre.
Recording: YouTube / Audio / Slides
Mitchell Warren, AVAC Executive Director, wrote about this topic in Science Speaks. Read "Will a vaccine crisis of confidence impact the global response to HIV?"
HVAD Toolkit
We created a toolkit to help you understand the current state of HIV vaccine research and to help you conduct outreach of your own. We’re especially excited this year about a set of infographics that explain key aspects of vaccine research—trial participant and enrollment numbers, global funding, trials timelines and more.
- HIV Vaccine Factsheet (May 2019)
- HIV Vaccine Key Messages (May 2019)
- Vaccines 101 Presentation (May 2019)
- HIV Vaccine R&D in 2019 Slide Deck
Infographics
- Vaccine Efficacy Trials Pipeline
- HIV Vaccine Research Pipeline
- Vaccine Strategies in the Pipeline
- Broadly Neutralizing Antibody Combinations
- HIV Vaccine Trial Participation in 2019
- HIV-Specific Neutralizing Antibodies: Targets and research status
- Total Vaccine Spending by Area
- Top HIV Vaccine Funders
Other Materials
- Will a Vaccine Crisis of Confidence Impact the Global Response to HIV? — a blog post by AVAC Executive Director Mitchell Warren appearing on Science Speaks
- Let’s Talk About It! HIV Vaccines – New York State Department of Health AIDS Institute Clinical Education Initiative Facebook Live interview with AVAC’s Stacey Hannah
- Meet the Lead Scientist on a Promising Female-Focused HIV Vaccine Trial — Q&A with Glenda Gray by Janssen
- HIV Vaccine Awareness Day 2019 — NIH blog post authored by Anthony Fauci and Maureen Goodenow
- Special Issue on HIV Vaccine Science in Africa, for Africa — IAVI Report
- HIV Vaccine Awareness Day 2019 Toolkit — IAVI
- What does Self-Reliance look like on the way to an HIV Vaccine? — USAID Office of HIV & AIDS Research Blog
- The Rise of Broadly Neutralizing Antibodies — Blog by Bill Snow
- The Stories of HIV Vaccines in 2018: From science to stakeholder engagement — AVAC Resource
- More Needs to be Done in HIV Fight — Kaleebu — article in New Vision